Mode of action studies for a novel anti-leishmania compound
Ontology highlight
ABSTRACT: We describe the development of a novel anti-leishmanial drug-like chemical series based on a pyrazolopyrimidine scaffold. The leading compound is efficacious in a mouse model of visceral leishmaniasis, and has suitable physicochemical, pharmacokinetic and toxicological properties for further development and has been declared a preclinical candidate. Detailed mode of action studies indicate that compounds from this series act principally by inhibiting the parasite protein kinases.
INSTRUMENT(S): LTQ Orbitrap Velos
ORGANISM(S): Leishmania Donovani
DISEASE(S): Visceral Leishmaniasis
SUBMITTER: Michael Urbaniak
LAB HEAD: Ian H Gilbert
PROVIDER: PXD009711 | Pride | 2018-11-30
REPOSITORIES: Pride
ACCESS DATA